Table 2.
Basic parameters for vascular studies
| Vessel diameter prior to constriction (μm) | Vessel diameter post constriction (μm) | ET‐1 needed to achieve desired constriction (nM) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Mean | SEM | n | Mean | SEM | n | Mean | SEM | n | |
| Control | 111.2 | 15.6 | 6 | 62.1 | 6.2 | 6 | 0.25 | 0.05 | 6 |
| L‐NAME | 86.9 | 11.5 | 7 | 59.5 | 5.4 | 7 | 0.15 | 0.04 | 7 |
| Peg‐Cat | 122.4 | 8.5 | 6 | 58.4 | 6.6 | 6 | 0.28 | 0.06 | 6 |
| LPA | 181.4 | 16.3 | 10 | 106.3 | 11.0 | 10 | 0.39 | 0.06 | 10 |
| LPA + L‐NAME | 184.9 | 22.9 | 7 | 121.3 | 20.6 | 7 | 0.48* | 0.12 | 7 |
| LPA + Peg‐Cat | 165.3 | 11.8 | 7 | 74.6 | 5.9 | 7 | 0.31 | 0.06 | 7 |
| SNP Control | 123.3 | 8.8 | 6 | 62.8 | 6.3 | 6 | 0.39 | 0.09 | 6 |
| SNP + LPA | 130.9 | 9.0 | 5 | 61.0 | 8.9 | 5 | 0.40 | 0.05 | 5 |
| Ach control | 135.0 | 18.0 | 5 | 70.0 | 9.0 | 5 | 0.27 | 0.04 | 5 |
| Ach + LPA | 109.5 | 20.0 | 5 | 58.1 | 11.5 | 5 | 0.15 | 0.03 | 5 |
| Ki16425 + LPA | 165.1 | 12.5 | 6 | 90.8 | 9.5 | 6 | 0.54* | 0.11 | 6 |
| Ki16425 + LPA + L‐NAME | 133.4 | 13.8 | 7 | 86.0 | 13.0 | 7 | 0.39* | 0.04 | 7 |
| Ki16425 + LPA + Peg‐Cat | 122.8 | 10.7 | 7 | 71.5 | 8.2 | 7 | 0.41 | 0.04 | 7 |
| H2L5186303 + LPA | 117.7 | 14.6 | 6 | 76.5 | 9.7 | 6 | 0.48* | 0.08 | 6 |
| H2L5186303 + LPA + L‐NAME | 123.6 | 14.7 | 6 | 73.0 | 10.4 | 6 | 0.30 | 0.07 | 6 |
| H2L5186303 + LPA + Peg‐Cat | 145.9 | 22.0 | 6 | 82.4 | 13.3 | 6 | 0.43 | 0.11 | 6 |
| Rotenone + LPA | 115.7 | 4.7 | 7 | 68.4 | 5.4 | 7 | 0.52 | 0.08 | 7 |
Mean diameter prior to constriction, post constriction and concentration of ET‐1 needed to achieve desired constriction across all vascular experiments. n = number of patients. Comparisons were made between studies without LPA (greyed out) and corresponding studies with LPA + intervention.
*
P < 0.05 for L‐NAME versus LPA + L‐NAME, control versus Ki16425 + LPA, L‐NAME versus Ki16425 + LPA + L‐NAME, control versus H2L5186303 + LPA, L‐NAME versus H2L5186303 + LPA + L‐NAME.